{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T02:02:57Z","timestamp":1782698577572,"version":"3.54.5"},"reference-count":66,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:00:00Z","timestamp":1688342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Endometrial cancer affects the uterus and is becoming increasingly common and deadly. Although surgery and adjuvant pelvic radiotherapy can often cure the disease when it is contained in the uterus, patients with metastatic or recurrent disease have limited response rates to chemotherapy, targeted agents, and hormonal therapy. To address this unmet clinical need, innovative treatment strategies are needed, and a growing focus on the immunomodulation of the tumor microenvironment has arisen. Current data suggest that active and\/or passive immunotherapy may be promising for the treatment of endometrial cancer.<\/jats:p>","DOI":"10.3390\/life13071502","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T01:32:18Z","timestamp":1688434338000},"page":"1502","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The Evolving Landscape of Immunotherapy in Uterine Cancer: A Comprehensive Review"],"prefix":"10.3390","volume":"13","author":[{"given":"Bashar Haj","family":"Hamoud","sequence":"first","affiliation":[{"name":"Department for Gynecology, Obstetrics and Reproductive Medicine, Saarland University Hospital, 66421 Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina Marina","family":"Sima","sequence":"additional","affiliation":[{"name":"\u201cBucur Maternity\u201d Obstetrics and Gynecology Discipline, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ileana Adela","family":"Vacaroiu","sequence":"additional","affiliation":[{"name":"\u201cSfantul Ioan\u201d Emergency Hospital Nephrology Discipline, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1601-0580","authenticated-orcid":false,"given":"Mihai-Teodor","family":"Georgescu","sequence":"additional","affiliation":[{"name":"\u201cProf. Dr. Al. Trestioreanu\u201d Oncology Discipline, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6662-7354","authenticated-orcid":false,"given":"Anca","family":"Bobirca","sequence":"additional","affiliation":[{"name":"\u201cDr. I. Cantacuzino\u201d Clinical Hospital Internal Medicine and Rheumatology Discipline, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Gaube","sequence":"additional","affiliation":[{"name":"\u201cMatei Bals\u201d Institute of Infectious Diseases, 021105 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8944-3857","authenticated-orcid":false,"given":"Florin","family":"Bobirca","sequence":"additional","affiliation":[{"name":"\u201cDr. Ion Cantacuzino\u201d Surgery Discipline, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragos-Eugen","family":"Georgescu","sequence":"additional","affiliation":[{"name":"\u201cDr. Ion Cantacuzino\u201d Surgery Discipline, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/IGC.0000000000000075","article-title":"Reproductive factors and the risk of endometrial cancer","volume":"24","author":"Ali","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrc3878","article-title":"Milestones of Lynch syndrome: 1895\u20132015","volume":"15","author":"Lynch","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_4","first-page":"1557","article-title":"Dosimetric influence of uterus position in cervix cancer high-dose-rate brachytherapy","volume":"61","author":"Georgescu","year":"2016","journal-title":"Rom. J. Phys."},{"key":"ref_5","first-page":"90","article-title":"Variation in uterus position prior to brachytherapy of the cervix: A case report","volume":"10","author":"Georgescu","year":"2017","journal-title":"J. Med. Life"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1159\/000511564","article-title":"Changing the Prognosis of Metastatic Cervix Uteri Adenosquamous Carcinoma through a Multimodal Approach: A Case Report","volume":"13","author":"Georgescu","year":"2020","journal-title":"Case Rep. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","article-title":"Two pathogenetic types of endometrial carcinoma","volume":"15","author":"Bokhman","year":"1983","journal-title":"Gynecol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"90532","DOI":"10.18632\/oncotarget.20042","article-title":"Checkpoint inhibitors in endometrial cancer: Preclinical rationale and clinical activity","volume":"8","author":"Mitica","year":"2017","journal-title":"Oncotarget"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network, Kandoth, C., Schultz, N., Cherniack, A.D., Akbani, R., and Liu, Y. (2013). Integrated genomic characterization of endometrial carcinoma. Nature, 497, 67\u201373.","DOI":"10.1038\/nature12113"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/PAS.0000000000001020","article-title":"Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups","volume":"42","author":"Bosse","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancers","volume":"113","author":"Talhouk","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ygyno.2015.07.018","article-title":"A Phase II Evaluation of Cediranib in the Treatment of Recurrent or Persistent Endometrial Cancer: An NRG Oncology\/Gynecologic Oncology Group Study","volume":"138","author":"Bender","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ctrv.2006.10.007","article-title":"Systemic therapy in metastatic or recurrent endometrial cancer","volume":"33","author":"Pectasides","year":"2007","journal-title":"Cancer Treat. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1586\/era.09.54","article-title":"Systemic therapy for recurrent endometrial cancer: A review of North American trials","volume":"9","author":"Dellinger","year":"2009","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ygyno.2010.02.007","article-title":"Treatment options for advanced endometrial carcinoma","volume":"117","author":"Dizon","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/mutage\/geu073","article-title":"Paradigm shift in oncology: Targeting the immune system rather than cancer cells","volume":"30","author":"Shekarian","year":"2015","journal-title":"Mutagenesis"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2174\/1574892810666150504121000","article-title":"Immune checkpoint inhibition: Therapeutic implications in epithelial ovarian cancer","volume":"10","author":"Longoria","year":"2015","journal-title":"Recent Pat. Anti-Cancer Drug Discov."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1600-0897.2010.00842.x","article-title":"Sex hormone regulation of innate immunity in the female reproductive tract: The role of epithelial cells in balancing reproductive potential with protection against sexually transmitted pathogens","volume":"63","author":"Wira","year":"2010","journal-title":"Am. J. Reprod. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jri.2014.12.006","article-title":"The immune system in the normal endometrium and implications for endometrial cancer development","volume":"109","author":"Vanderstraeten","year":"2015","journal-title":"J. Reprod. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2011.09.039","article-title":"Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis","volume":"124","author":"Hwang","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1600-0897.1982.tb00086.x","article-title":"Morphologic Correlates of Host Response in Endometrial Carcinoma","volume":"2","author":"Deligdisch","year":"1982","journal-title":"Am. J. Reprod. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/1097-0142(19820401)49:7<1504::AID-CNCR2820490733>3.0.CO;2-9","article-title":"Endometrial carcinoma in Miyagi Prefecture, Japan: Histopathologic analysis of a cancer registry-based series and comparison with cases in American women","volume":"49","author":"Silverberg","year":"1982","journal-title":"Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/1097-0142(19920315)69:6<1424::AID-CNCR2820690620>3.0.CO;2-5","article-title":"Combined assessment of vascular and myometrial invasion as a model to predict prognosis in stage I endometrioid adenocarcinoma of the uterine corpus","volume":"69","author":"Ambros","year":"1992","journal-title":"Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1158\/1078-0432.CCR-0732-3","article-title":"Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma","volume":"10","author":"Kondratiev","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ygyno.2009.03.022","article-title":"Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer","volume":"114","author":"Leffers","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1097\/IGC.0b013e31822c271f","article-title":"Immunofluorescence-Detected Infiltration of CD4+FOXP3+ Regulatory T Cells is Relevant to the Prognosis of Patients with Endometrial Cancer","volume":"21","author":"Yamagami","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ygyno.2008.04.021","article-title":"The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer","volume":"110","author":"Giatromanolaki","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ygyno.2014.08.028","article-title":"Prognostic significance of tumor-associated macrophages in endometrial adenocarcinoma","volume":"135","author":"Ayub","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5777","DOI":"10.1002\/cncr.25371","article-title":"Clinical significance of regulatory T cells and CD8+ effector populations in patients with human endometrial carcinoma","volume":"116","author":"Chang","year":"2010","journal-title":"Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00262-014-1537-8","article-title":"Mapping the immunosuppressive environment in uterine tumors: Implications for immunotherapy","volume":"63","author":"Vanderstraeten","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ygyno.2014.10.012","article-title":"Tumor-associated macrophages: Co-conspirators and orchestrators of immune suppression in endometrial adenocarcinoma","volume":"135","author":"Zsiros","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/PGP.0b013e318284e198","article-title":"Infiltration of tumor-associated macrophages is increased in the epithelial and stromal compartments of endometrial carcinomas","volume":"32","author":"Dun","year":"2013","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1447-0756.2012.02036.x","article-title":"Tumor-associated macrophages correlate with progesterone receptor loss in endometrial endometrioid adenocarcinoma","volume":"39","author":"Jiang","year":"2013","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/(SICI)1097-0215(19991022)84:5<538::AID-IJC17>3.0.CO;2-B","article-title":"Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas","volume":"84","author":"Salvesen","year":"1999","journal-title":"Int. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ygyno.2007.12.033","article-title":"Tumor-associated macrophages correlate with vascular space invasion and myometrial invasion in endometrial carcinoma","volume":"109","author":"Soeda","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrclinonc.2014.111","article-title":"Therapeutic vaccines for cancer: An overview of clinical trials","volume":"11","author":"Melero","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ygyno.2008.08.032","article-title":"Wilms\u2019 tumor gene 1 (WT1) in endometrial carcinoma","volume":"111","author":"Coosemans","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"ref_39","first-page":"4779","article-title":"Wilms\u2019 tumor 1 (WT1) peptide immunotherapy for gynecological malignancy","volume":"29","author":"Ohno","year":"2009","journal-title":"Anticancer Res."},{"key":"ref_40","first-page":"5495","article-title":"Wilms\u2019 Tumor Gene 1 (WT1)\u2014Loaded dendritic cell immunotherapy in patients with uterine tumors: A phase I\/II clinical trial","volume":"33","author":"Coosemans","year":"2013","journal-title":"Anticancer Res."},{"key":"ref_41","first-page":"3709","article-title":"Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma","volume":"30","author":"Coosemans","year":"2010","journal-title":"Anticancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"15772","DOI":"10.18632\/oncotarget.4694","article-title":"Oncogenic cancer\/testis antigens: Prime candidates for immunotherapy","volume":"6","author":"Gjerstorff","year":"2015","journal-title":"Oncotarget"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/ijc.10585","article-title":"Cancer-testis antigen expression in uterine malignancies with an emphasis on carcinosarcomas and papillary serous carcinomas","volume":"101","author":"Resnick","year":"2002","journal-title":"Int. J. Cancer"},{"key":"ref_44","first-page":"16","article-title":"SSX expression in gynecological cancers and antibody response in patients","volume":"4","author":"Hasegawa","year":"2004","journal-title":"Cancer Immun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1158\/1078-0432.CCR-05-1206","article-title":"A novel cancer testis antigen that is frequently expressed in pancreatic, lung, and endometrial cancers","volume":"12","author":"Okada","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"14453","DOI":"10.1073\/pnas.0606512103","article-title":"Recombinant vaccinia\/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients","volume":"103","author":"Karbach","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","first-page":"1271","article-title":"Overexpression of HER-2\/neu in uterine serous papillary cancer","volume":"8","author":"Santin","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"ref_48","first-page":"27","article-title":"Immunotherapy treatment landscape for patients with endometrial cancer: Current evidence and future opportunities","volume":"21","author":"Eskander","year":"2023","journal-title":"Clin. Adv. Hematol. Oncol. H&O"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40661-015-0020-3","article-title":"Immunotherapy in endometrial cancer\u2014An evolving therapeutic paradigm","volume":"2","author":"Longoria","year":"2015","journal-title":"Gynecol. Oncol. Res. Pract."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11864-017-0504-y","article-title":"Immunotherapy in Gynecologic Cancers: Are We There Yet?","volume":"18","author":"Pakish","year":"2017","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40364-021-00301-z","article-title":"Immunotherapy in endometrial cancer: Rationale, practice and perspectives","volume":"9","author":"Cao","year":"2021","journal-title":"Biomark. Res."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Pir\u0161, B., \u0160kof, E., Smrkolj, V., and Smrkolj, \u0160. (2022). Overview of Immune Checkpoint Inhibitors in Gynecological Cancer Treatment. Cancers, 14.","DOI":"10.3390\/cancers14030631"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1200\/EDBK_237967","article-title":"Immunotherapy in Gynecologic Cancers: What We Know Now and Where We Are Headed","volume":"39","author":"Levinson","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1016\/j.apsb.2021.02.007","article-title":"Applying artificial intelligence for cancer immunotherapy","volume":"11","author":"Xu","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40425-017-0218-5","article-title":"Combination immunotherapy: A road map","volume":"5","author":"Ott","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Drakes, M.L., Czerlanis, C.M., and Stiff, P.J. (2020). Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs. Cancers, 12.","DOI":"10.3390\/cancers12113301"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Morand, S., Devanaboyina, M., Staats, H., Stanbery, L., and Nemunaitis, J. (2021). Ovarian Cancer Immunotherapy and Personalized Medicine. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22126532"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/GRF.0000000000000513","article-title":"Immunotherapy for Gynecologic Cancer: Current Applications and Future Directions","volume":"63","author":"Lynam","year":"2020","journal-title":"Clin. Obstet. Gynecol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2020.04.043","article-title":"Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification","volume":"158","author":"Kim","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"955","DOI":"10.20892\/j.issn.2095-3941.2021.0032","article-title":"Personalized immunotherapy in cancer precision medicine","volume":"18","author":"Kiyotani","year":"2021","journal-title":"Cancer Biol. Med."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Bobirc\u0103, A., Bobirc\u0103, F., Ancuta, I., Florescu, A., P\u0103dureanu, V., Florescu, D.N., P\u0103dureanu, R., Florescu, A., and Mu\u0219etescu, A.E. (2021). Rheumatic Immune-Related Adverse Events-A Consequence of Immune Checkpoint Inhibitor Therapy. Biology, 10.","DOI":"10.3390\/biology10060561"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"17588359211008399","DOI":"10.1177\/17588359211008399","article-title":"Cell therapies in ovarian cancer","volume":"13","author":"Sarivalasis","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41467-018-03730-x","article-title":"Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers","volume":"9","author":"McGrail","year":"2018","journal-title":"Nat. Commun."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/7\/1502\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:05:18Z","timestamp":1760126718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/7\/1502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,3]]},"references-count":66,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["life13071502"],"URL":"https:\/\/doi.org\/10.3390\/life13071502","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,3]]}}}